Home/Candel Therapeutics/Francesco G. Marincola
FG

Francesco G. Marincola

Chief Scientific Officer

Candel Therapeutics

Therapeutic Areas

Candel Therapeutics Pipeline

DrugIndicationPhase
CAN-2409Non-Small Cell Lung Cancer (NSCLC)Phase 3
CAN-3110Recurrent High-Grade GliomaPhase 1